

Immunostimulatory effects of dairy probiotic strains *Bifidobacterium animalis* ssp. *lactis* HY8002 and *Lactobacillus plantarum* HY7717

Ju-Yeon Kim, Joo Yun Kim, Hyeonji Kim, Eun Chae Moon, Keon Heo*, Jae-Jung Shim and Jung-Lyoul Lee

R&BD Center, hy Co., Ltd., Yongin 17086, Korea



Received: Jun 8, 2022
Revised: Oct 5, 2022
Accepted: Oct 13, 2022

*Corresponding author

Keon Heo
R&BD Center, hy Co., Ltd., Yongin
17086, Korea.
Tel: +82-70-7835-6040
E-mail: gunny@hy.co.kr

Copyright © 2022 Korean Society of Animal Sciences and Technology. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/4.0/>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ORCID

Ju-Yeon Kim
<https://orcid.org/0000-0003-3518-3639>
Joo Yun Kim
<https://orcid.org/0000-0002-5534-2871>
Hyeonji Kim
<https://orcid.org/0000-0002-6923-6113>
Eun Chae Moon
<https://orcid.org/0000-0002-6480-8186>
Keon Heo
<https://orcid.org/0000-0001-5874-9389>
Jae-Jung Shim
<https://orcid.org/0000-0002-9301-6583>
Jung-Lyoul Lee
<https://orcid.org/0000-0001-9800-2474>

Competing interests

No potential conflict of interest relevant to this article was reported.

Funding sources

Not applicable.

Abstract

Previous studies reported that *Bifidobacterium animalis* ssp. *lactis* HY8002 (HY8002) improved intestinal integrity and had immunomodulatory effects. *Lactobacillus plantarum* HY7717 (HY7717) was screened *in vitro* from among 21 other lactic acid bacteria (LAB) and demonstrated nitric oxide (NO) production. The aims of this study were to investigate the individual and combined *ex vivo* and *in vivo* effects of LAB strains HY8002 and HY7717 at immunostimulating mice that have been challenged with an immunosuppressant drug. The combination of HY8002 and HY7717 increased the secretion of cytokines such as interferon (IFN)- γ , interleukin (IL)-12, and tumor necrosis factor (TNF)- α in splenocytes. In a cyclophosphamide (CTX)-induced immunosuppression model, administration of the foregoing LAB combination improved the splenic and hematological indices, activated natural killer (NK) cells, and up-regulated plasma immunoglobulins and cytokines. Moreover, this combination treatment increased Toll-like receptor 2 (TLR2) expression. The ability of the combination treatment to upregulate IFN- γ and TNF- α in the splenocytes was inhibited by anti-TLR2 antibody. Hence, the immune responses stimulated by the combination of HY8002 and HY7717 are associated with TLR2 activation. The preceding findings suggest that the combination of the HY8002 and HY7717 LAB strains could prove to be a beneficial and efficacious immunostimulant probiotic supplement. The combination of the two probiotic strains will be applied on the dairy foods including yogurt and cheese.

Keywords: Immune, Immunostimulation, Cytokines, Toll-like receptor, Cyclophosphamide

INTRODUCTION

The immune system comprises innate and adaptive immunity. It is a tightly regulated network that maintains homeostasis under normal physiological conditions [1]. Lymphocytes and macrophages play vital roles in both types of immunity [2,3]. Natural killer (NK) cells are key components of innate immunity and guard the host against tumors and viral infections. T and B lymphocytes are primary effectors in adaptive immunity [4]. Activated lymphocytes and macrophages produce inflammatory mediators such as nitric oxide (NO), tumor necrosis factor (TNF)- α , interferon (IFN)- γ , and

Acknowledgements

Not applicable.

Availability of data and material

Upon reasonable request, the datasets of this study can be available from the corresponding author.

Authors' contributions

Conceptualization: Kim Ju-Yeon, Kim Joo Yun, Shim JJ, Lee JL.

Data curation: Heo K.

Formal analysis: Kim Joo Yun.

Methodology: Kim Ju-Yeon.

Software: Kim Ju-Yeon.

Validation: Kim Ju-Yeon, Kim Joo Yun.

Investigation: Kim Ju-Yeon, Kim Joo Yun, Kim H, Moon EC.

Writing - original draft: Kim Ju-Yeon.

Writing - review & editing: Kim Ju-Yeon, Kim Joo Yun, Kim H, Moon EC, Heo K, Shim JJ, Lee JL.

Ethics approval and consent to participate

This research has been approved by the Institutional Animal Care and Use Committee (IACUC) (approval number: AEC-2021-0009-Y).

interleukin (IL)-12 [5–7].

Probiotics are living microorganisms that provide various health benefits to the host, and lactic acid bacteria (LAB) such as *Lactobacillus* and *Bifidobacterium* are known as common probiotic bacterial species [8,9]. Particularly, the immunomodulatory efficacy of probiotics has aroused much research interest in recent years [10,11]. However, their effects on the immune system widely vary even among strains within the same species. Hence, characterizing the effects of specific strains and determining their optimal doses and combinations are necessary to validate the health claims [12]. Previous studies have demonstrated that LAB-induced immunomodulatory responses are mediated through pattern recognition receptors (PRRs) expressed on immune cells, such as toll-like receptors (TLRs) [13–15]. However, even in the same species of LAB, the PRRs mainly involved are different depending on the strain, and the immunomodulatory effect may appear in various ways, such as immunostimulation and immunoregulation [16].

Cyclophosphamide (CTX) is an antineoplastic and immunosuppressive drug administered for various cancers and autoimmune diseases [17,18]. However, it produces activated metabolites that interfere with DNA replication and damage mitochondrial and lysosomal membranes, which can injure normal cells as well as cancer cells [19]. The CTX-induced cytotoxicity may generate various side effects such as hematological malignancies, infections, and bone marrow depression [20]. Hence, researchers have investigated immunoregulatory agents such as functional foods and dietary supplements that mitigate the side effects of chemotherapeutic agents [21].

Bifidobacterium animalis ssp. *lactis* HY8002 (HY8002) is a probiotic strain confirmed to improve intestinal integrity disturbed by antibiotics [22] and reduce airway hypersensitivity and inflammatory response caused by fine dust [23]. Nevertheless, its effect and mechanism on the systemic immune response are unclear. In addition, *Lactobacillus plantarum* HY7717 (HY7717) was selected as a new potential immunostimulatory candidate. Although there have been studies on the immunostimulatory effects of individual strains of probiotics, there is insufficient evidence on the effects of the combination of *Bifidobacterium* and *Lactobacillus* strains on systemic immunity and immunosuppression improvement [24–27]. Therefore, we explored possible synergy of efficacy between verified probiotic *Bifidobacterium* strain HY8002 and the newly selected *Lactobacillus* strain HY7717 in mouse primary splenocytes and CTX-induced immunosuppressed mice and aimed to elucidate their molecular mechanisms.

MATERIALS AND METHODS

Materials

Roswell Park Memorial Institute (RPMI) 1640 medium, Dulbecco's modified Eagle minimal essential medium (DMEM), antibiotic-antimycotic, and fetal bovine serum (FBS) were obtained from Gibco (Grand Island, NY, USA). Griess reagent, levamisole hydrochloride (LH), CTX, concanavalin A (Con A), and lipopolysaccharide (LPS) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Enzyme-linked immunosorbent assay (ELISA) kits for IFN- γ , IL-12, and TNF- α were acquired from BD Biosciences (San Diego, CA, USA). ELISA kits for IgA and IgG were procured from Abcam (Cambridge, MA, USA) and Invitrogen (Carlsbad, CA, USA), respectively. Anti-mouse TLR2 monoclonal antibody (mAb) (clone C9A12. No. mabg-mtlr2) and anti-mouse TLR4 mAb (clone MTS510. No. 117617) were obtained from InvivoGen (San Diego, CA, USA) and BioLegend (San Diego, CA, USA), respectively.

Bacterial strain preparation

LAB strains including *B. animalis* ssp. *lactis* HY8002 and *L. plantarum* HY7717 were stored in

the seed culture library of hy (Yongin, Korea). *Bifidobacterium* strains and *Lactobacillus* strains were anaerobically cultured in blood glucose liver (BL) broth or de Man Rogosa and Sharpe (MRS) broth at 37°C for 18 h. The cultured LAB strains were centrifuged at 2,000×g for 15 min and then resuspended in PBS (phosphate buffered saline) for subsequent experiments.

Nitric oxide assay

NO release was indirectly detected by measuring stable NO catabolites in cell culture media via the Griess reaction. RAW 264.7 macrophages were plated into 96-well plates at 1.0×10^4 cells/well and treated with LAB strains (1.0×10^5 cells/well) for 24 h. The cell culture medium was mixed with an equal amount of Griess reagent and left in the dark at room temperature for 15 min. Absorbance was measured at 540 nm and the NO quantity was determined by interpolation of a sodium nitrite standard curve.

Cytokine determination in splenocyte

Splenocytes were isolated from aseptically collected mouse spleens through a 40 µm cell strainer, and then plated at 1.0×10^6 cells/well in RPMI 1640 medium in a 24-well plate. Each well was treated with 1.0×10^7 CFU/mL of HY8002, HY7717, or a 1:1 mixture of HY8002 and HY7717, and then cultured at 37°C under 5% CO₂ conditions for 24 to 48 h. Cytokine levels in the culture medium were determined with ELISA kits according to the manufacturer's instructions.

Real-time quantitative polymerase chain reaction assay

RNA was extracted using an Easy-BLUETM Total Extraction kit (iNtRON Biotechnology, Seongnam, Korea). The cDNA was synthesized with an Omniscript® Reverse Transcription kit (Qiagen, Hilden, Germany) on a thermal cycler (Bio-Rad Laboratories, Hercules, CA, USA). The mRNA levels were measured using a TaqMan Universal PCR Master Mix (Applied Biosystems, Foster City, CA, USA) and a QuantStudio 6 Real-Time PCR System (Applied Biosystems). The TLR2 (Mm00442346_m1), TLR4 (Mm00445273_m1), and GAPDH (Mm99999915_g1) transcripts were quantified with gene-specific primers.

Animal experiment

Male Balb/c mice (7 weeks; 20–22 g) were obtained from Dooyeol Biotech (Seoul, Korea). The animal facility was maintained at 20°C–22°C, 40–60% relative humidity (RH), and 12 h light/12 h dark cycle. The mice had ad libitum access to an autoclaved standard laboratory diet and water. All experimental procedures were approved by the Ethics Review Committee of the R&D Center of hy Co. Ltd., Korea (IACUC approval number, AEC-2021-0009-Y). After 1 week adaptation, the mice were divided into six groups (n = 5): normal mice (NOR), CTX, LH (20 mg/kg/day), HY8002 (1×10^9 CFU/kg/day), HY7717 (1.0×10^9 CFU/kg/day), and HY8002+HY7717 (1:1 ratio; 1.0×10^9 CFU/kg/day). LH, HY8002, and HY7717 were intragastrically administered in sterile saline once daily for 8 day. All mice except those in the NOR group were intraperitoneally injected with 150 mg/kg/day CTX on day 8. At day 10, whole blood was collected in anticoagulant tubes, the plasma was isolated, and the spleens were excised and weighed.

Natural killer cell activity assay

Splenic NK cells were isolated by Magnetic-activated cell sorting (MACS) Cell separate kit with CD49b (DX5) MicroBeads (Miltenyi Biotec Technology, Bergisch Gladbach, Germany), placed in a 96-well round-bottom plate at a density of 1.0×10^5 cells/well and co-cultured with an equal density of YAC-1 cells for 16 h. Lactate dehydrogenase (LDH), as an indicator of NK cell

cytotoxicity against YAC-1, was measured using a CytoTox® 96 non-radioactive cytotoxicity assay kit (Promega, Madison, WI, USA).

Splenocyte proliferation assay

Splenocytes were prepared as previously described, plated into 96-well plates at a density of 2.0×10^5 cells/well, and subjected either to Con A (4 µg/mL) or LPS (1 µg/mL). After 48 h, cell counting kit-8 (CCK-8) solution was added and absorbances were measured at 450 nm.

Complete blood cell count

Blood counts were performed using an auto hematology analyzer (BC-5000 Vet; Mindray, Shenzhen, China).

Immunoglobulin and cytokine determination in plasma

Plasma IgA, IgG, and IL-12 levels were measured using ELISA kits according to the manufacturer's instructions.

Statistical analysis

Data are represented as means \pm SD for ≥ 3 independent experiments. Significant differences were identified by one-way analysis of variance (ANOVA) followed by the Newman-Keuls test ($p < 0.05$). An unpaired t-test was used to compare means between two independent groups. All statistical analyses were performed using GraphPad Prism v5 (San Diego, CA, USA).

RESULTS

Effects of lactic acid bacteria strains on nitric oxide production in RAW 264.7 macrophages

We tested the effects of 252 LAB strains on NO inhibition in RAW 264.7 macrophages. Of these, 21 demonstrated anti-inflammatory efficacy (data not shown) and their immunostimulatory function was evaluated. We measured NO concentrations in culture media to determine whether the 21 LAB strains activate RAW 264.7 (Fig. 1). Eleven of the strains increased the relative NO rates by > 30 -fold. Of these, HY7717 showed the largest NO rate increase (45.2-fold).

Effects of combined HY8002 plus HY7717 on splenocyte cytokines

We subjected splenocytes to single and combined HY8002 and HY7717 treatments and measured the IFN- γ , IL-12, and TNF- α levels using ELISA (Fig. 2). The cytokine levels in the splenocytes treated with all LAB strains were significantly higher than those in the vehicle control. Cytokine secretion was significantly higher in response to all combination treatments than each standalone treatment.

Effects of combined HY8002 and HY7717 administration on splenic and hematological indices of immunosuppressed mice

HY8002, HY7717, or a mixture of both was administered to CTX-immunosuppressed mice to assess the immunostimulatory efficacy of LAB strains under physiological conditions. The CTX treatment markedly reduced the spleen index (Fig. 3A). The spleen indices were significantly higher in the LH and HY8002+HY7717 groups than the CTX group. Oral administration of each strain alone non-significantly increased the spleen indices. We also measured the complete blood count (CBC) parameters in each group (Figs. 3B–3D). Compared with the NOR group, the




Fig. 1. Effects of HY7717 on NO production in RAW 264.7 macrophages. Cells were treated with 21 different *Lactobacillus* strains at 1.0×10^5 CFU/0.1 mL for 24 h. NO was detected in the culture media using the Griess assay. Data represent fold changes in NO production compared with untreated cells.




Fig. 2. Combined effects of HY8002 and HY7717 on cytokine production in mouse splenocytes. (A–C) Splenocytes isolated from normal mice were treated with HY8002, HY7717, their combination (1.0×10^7 CFU/mL) or LPS ($1 \mu\text{g/mL}$) for 24 h. The amounts of IFN- γ , IL-12, and TNF- α released into the culture media were measured using ELISA kits. Data are represented as means \pm SD of three independent experiments. * $p < 0.05$, ** $p < 0.01$, and *** $p < 0.001$ compared with the vehicle group. $^\dagger p < 0.05$, $^\ddagger p < 0.01$, and $^\dagger\dagger p < 0.001$ compared with the combination treatment. IFN, interferon; LPS, lipopolysaccharide; IL, interleukin; TNF, tumor necrosis factor.

white blood cells (WBC) and red blood cells (RBC) counts and Lymph% in the CTX group were significantly reduced by 36.4%, 79.4%, and 29.9%, respectively. LH administration significantly increased the relative WBC count and Lymph% but not the RBC count. The HY8002, HY7717, and HY8002+HY7717 groups presented with significantly higher WBC counts than the CTX group. The HY8002+HY7717 group presented with significantly higher Lymph% and RBC counts than the CTX group. However, the HY8002 and HY7717 groups presented with non-significantly higher Lymph% and RBC counts than the CTX group.

Effects of combined HY8002 and HY7717 administration on natural killer cell activity and splenocyte proliferation in immunosuppressed mice

NK cell activity and T and B cell proliferation were assessed for the spleens of all treatment groups. The CTX treatment significantly decreased NK cell cytotoxicity against its YAC-1 target cell (Fig. 4). However, the LH treatment restored NK cell activity. All LAB treatments significantly increased NK cell activity. However, the combination treatments were significantly more efficacious than the




Fig. 3. Combined effects of orally administered HY8002 and HY7717 on spleen weight and hematological indices in CTX-immunosuppressed mice. (A) The spleen index was calculated as [index = spleen weight (mg) / body weight (g)]. (B–D) Blood was collected to determine complete blood cell count. Data are means \pm SD (n = 5). ###*p* < .001 compared with the normal group. **p* < 0.05, ***p* < 0.01, and ****p* < 0.001 compared with the CTX-induced group. †*p* < 0.05 and ††*p* < 0.01 compared with the combination treatment. NOR, normal mice; CTX, cyclophosphamide; LH, levamisole hydrochloride; WBC, white blood cells; RBC, red blood cells.

single treatments. Splenic lymphocytes were incubated with Con A and LPS to evaluate T and B lymphocyte proliferation, respectively (Fig. 5). LH reversed CTX-induced inhibition of T and B lymphocyte proliferation. Standalone HY8002 and HY7717 and their combination significantly increased T and B lymphocyte proliferation compared with the CTX group. Moreover, combined LAB strain administration significantly enhanced T and B lymphocyte proliferation compared with each standalone LAB treatment.

Effects of combined HY8002 and HY7717 administration on immunoglobulins and cytokines in immunosuppressed mice

We quantified the relative plasma IgA and IgG levels (Fig. 6). Oral LH administration significantly increased IgA and IgG reduced by CTX treatment. No standalone LAB strain significantly altered the IgA levels whereas the combinations did significantly raise them. All LAB treatments significantly increased the IgG levels compared with the CTX group. However, the combination treatments significantly and more effectively increased the IgG levels than the standalone treatments. We measured IFN- γ and IL-12 secretion in cultured Con A- or LPS-stimulated splenic lymphocytes (Figs. 7A–7D). The LH and HY8002+HY7717 treatments increased the cytokine levels reduced by the CTX treatments in the Con A-activated T lymphocytes and the LPS-activated B lymphocytes. The cytokine levels in the Con A-activated T lymphocytes of




Fig. 4. Combined effects of orally administered HY8002 and HY7717 on NK cell activity in CTX-immunosuppressed mice. Data are means \pm SD ($n = 5$). $###p < 0.001$ compared with the NOR group. $**p < 0.01$ and $***p < 0.001$ compared with the CTX group. $††p < 0.01$ compared with the combination treatment. NK, natural killer; NOR, normal mice; CTX, cyclophosphamide; LH, levamisole hydrochloride.




Fig. 5. Combined effects of orally administered HY8002 and HY7717 on splenocyte proliferation in CTX-immunosuppressed mice. (A, B) Mouse splenocytes were stimulated with Con A ($4 \mu\text{g/mL}$) or LPS ($1 \mu\text{g/mL}$) for 48 h. Data are means \pm SD ($n = 5$). $###p < 0.001$ compared with the NOR group. $*p < 0.05$, $**p < 0.01$ and $***p < 0.001$ compared with the CTX group. $†p < 0.05$ and $††p < 0.01$ compared with the combination treatment. LPS, lipopolysaccharide; NOR, normal mice; CTX, cyclophosphamide; LH, levamisole hydrochloride.

HY8002+HY7717 group were significantly higher than those of standalone LAB groups. The IFN- γ levels in the LPS-activated B lymphocytes of HY7717 or HY8002+HY7717 groups were significantly higher than those of CTX group. Only HY8002+HY7717 administration significantly increased the relative IL-12 levels in the LPS-activated B lymphocytes. The HY8002, HY7717, HY8002+HY7717, and LH treatments recovered the plasma IL-12 levels reduced by CTX treatment (Fig. 7E).

Toll-like receptor2-mediated cytokine responses in splenocytes subjected to the HY8002 and HY7717 combination

TLR2/4 mRNA expression levels in splenocytes treated with single and combined HY8002 and HY7717 were measured to determine whether the immunostimulant efficacy of these LAB is associated with TLRs (Figs. 8A and 8B). Each standalone LAB strain slightly upregulated TLR2 mRNA but the combination treatment significantly upregulated it. The HY7717 treatment non-significantly upregulated TLR4 mRNA. After pretreatment with anti-TLR2 or anti-TLR4




Fig. 6. Combined effects of orally administered HY8002 and HY7717 on immunoglobulin levels in CTX-immunosuppressed mice. (A, B) Plasma IgA and IgG levels were assayed using ELISA kits. Data are represented as means \pm SD (n = 5). #p < 0.05 and ###p < 0.001 compared with the NOR group. *p < 0.05, **p < 0.01, and ***p < 0.001 compared with the CTX group. †p < 0.05 compared with the combination treatment. IgG, immunoglobulin; NOR, normal mice; CTX, cyclophosphamide; LH, levamisole hydrochloride.

antibodies, the IFN- γ , IL-12, and TNF- α levels were measured in the culture media of splenocytes subjected to HY8002, HY7717, or their combination (Figs. 8C–8E). Anti-TLR2 or anti-TLR4 antibody alone had no significant inhibitory effect on the cytokine levels. Splenocytes blocked with anti-TLR2 antibody secreted significantly less IFN- γ and TNF- α than those also treated with LAB. Anti-TLR4 antibody blocked IFN- γ and TNF- α production only in the HY7717-treated splenocytes. However, neither antibody had any significant effect on IL-12 secretion.

DISCUSSION

There has been growing interest in the immunomodulatory potential of probiotics in the prevention and treatment of various complex symptoms [28]. Several LAB strains demonstrated health benefits by enhancing the immune system [29–31]. Certain LAB strains regulate T cell effector functions, enhance humoral immunity, and activate lymphocytes and macrophages [32]. Our previous work showed that the number of IFN- γ -secreting T cells was increased by co-culturing them with *Bifidobacterium animalis* ssp. *lactis* HY8002-treated dendritic cells [33]. Nevertheless, the immunostimulatory properties of HY8002 have not been thoroughly investigated. Here, we discovered that *Lactobacillus plantarum* HY7717 is a potential immunomodulatory agent and evaluated its immunostimulatory efficacy alone and in combination with HY8002 both *ex vivo* and *in vivo*.

Spleen is a significant organ in terms of understanding immune cell subpopulations and their immune responses to antigens. Splenocytes include T and B cells, macrophages, and natural killer (NK) cells [34]. Their immune responses include antigen presentation, T lymphocyte activation, and B lymphocyte differentiation [35]. Cytokines control immune cell proliferation and activity. Proinflammatory cytokines such as IFN- γ , IL-12, and TNF- α augment inflammatory responses [12]. IFN- γ is produced mainly by T and NK cells and activates macrophages, neutrophils, and other NK cells [36]. IL-12 is a heterodimeric protein released from antigen-presenting cells (APCs) such as dendritic cells, macrophages, and B cells and it activates NK and T cells [37]. TNF- α is produced mainly by activated macrophages, T cells, and NK cells and promotes inflammatory activity in macrophages [38]. Here, HY8002 and HY7717 stimulated IFN- γ , IL-12, and TNF- α




Fig. 7. Combined effects of orally administered HY8002 plus HY7717 on cytokine production in CTX-immunosuppressed mice. (A, B) Mouse splenocytes were stimulated with Con A (4 μ g/mL) for 48 h. IFN- γ (A) and IL-12 (B) levels in the culture medium were detected with ELISA kits. (C, D) Mouse splenocytes were stimulated with LPS (1 μ g/mL) for 48 h. IFN- γ (C) and IL-12 (D) levels in the culture medium were detected with ELISA kits. (E) Plasma IL-12 levels were assessed using an ELISA kit. [#] $p < 0.05$ and ^{###} $p < 0.001$ compared with the NOR group. ^{*} $p < 0.05$, ^{**} $p < 0.01$, and ^{***} $p < 0.001$ compared with the CTX group. [†] $p < 0.05$, ^{††} $p < 0.01$, and ^{†††} $p < 0.001$ compared with the combination treatment. IFN, interferon; NOR, normal mice; CTX, cyclophosphamide; LH, levamisole hydrochloride; IL, interleukin; LPS, lipopolysaccharide.

production in splenocytes. Moreover, the combination of HY8002 and HY7717 effectively increased cytokine production.

The mouse CTX-induced immunosuppression model is widely used to investigate immunomodulatory activity. CTX inhibits the immune response by inactivating immune cells and decreasing proinflammatory cytokine production [39]. Here, we investigated the immunomodulatory properties of HY8002 and HY7717 in a mouse CTX-induced




Fig. 8. Effects of HY8002 or HY7717 on TLR2-mediated cytokine production in mouse splenocytes. (A, B) Splenocytes isolated from normal mice were treated with HY8002, HY7717, or their combination (1.0×10^7 CFU/mL). Relative mRNA levels of TLR2 (A) and TLR4 (B) were normalized against that of GAPDH. (C–E) Mouse splenocytes were pretreated with anti-TLR2 or anti-TLR4 mAb for 1 h followed by HY8002, HY7717, or their combination treatment for 24 h. IFN- γ (C), IL-12 (D), and TNF- α (E) secretion in the culture media was determined with ELISA kits. * $p < 0.05$, ** $p < 0.01$, and *** $p < 0.001$ for pairwise treatment group comparisons. No Ab, Non-treated antibody; TLR2 Ab, Toll-like receptor 2 antibody; TLR4 Ab, Toll-like receptor 4 antibody. TLR, toll-like receptor; NO, nitric oxid; TNF, tumor necrosis factor; IFN, interferon; IL, interleukin.

immunosuppression model. LH is immunostimulatory, has several adverse effects, and was used as the positive control [40,41]. As the spleen is a major organ in the immune system, its size is a vital indicator of health and disease [42]. Moreover, changes in the lymphocyte count are used to diagnose immune-mediated disease [43]. Recent studies showed that red blood cells (RBCs) modulate immune cell activity and maturation [44,45]. In the present study, we confirmed that CTX induced immunosuppression by reducing spleen and hematological indices and verified that

administration of a combination of HY8002 and HY7717 increased these indices and counteracted the negative effects of CTX.

NK cells mediate antitumor and antiviral immune responses [46], by recognizing infected cells in the absence of major histocompatibility complex (MHC) and enable rapid immune responses. T and B lymphocyte proliferation is vital in adaptive immune system activation, and their proliferation in response to mitogens has been widely applied to evaluate the sensitivity of these cells [47]. Here, HY8002 and HY7717 effectively enhanced NK cell activity and T and B cell proliferation in CTX-treated mice.

Immunoglobulin A (IgA) is the first-line defense against infection while IgG is the major antibody in secondary responses. Proinflammatory cytokines play crucial roles in inflammation as a host defense mechanism. Inflammatory responses are beneficial when cytokines are secreted at appropriate level [36]. In the present study, a combination of HY8002 and HY7717 upregulated IgA and IgG in CTX-treated mice. It also increased IFN- γ and IL-12 secretion in Con A-activated T cells more than either treatment alone. The foregoing combination also increased IFN- γ and IL-12 production by LPS-activated B cells. Plasma IL-12 levels were higher in response to this combination than either treatment alone. Therefore, administration of HY8002 plus HY7717 resisted immunosuppression *in vivo*.

TLRs modulate both innate and adaptive immunity. Certain TLRs are co-stimulatory and increase proliferation and cytokine production in T cells stimulated by their respective ligands [48]. Another study demonstrated that TLR signaling is implicated in cytokine production by B cells, antigen presentation, Ig class switching, and B cell survival [49]. The bioactive factors and microbe-associated molecular patterns (MAMPs) produced by different LAB strains activate TLR2 [14,50]. Administration of certain LAB strains increased the relative numbers of TLR4⁺ and TLR2⁺ cells produced by mice [51]. Here, we investigated whether TLRs mediate HY8002 and HY7717 immune responses. The TLR2 mRNA expression levels increased in healthy splenocytes in response to a combination of HY8002 plus HY7717. By contrast, none of the treatments significantly modulated the TLR4 mRNA expression levels. We demonstrated that anti-TLR2 antibody blocked LAB-induced IFN- γ and TNF- α secretion but had no inhibitory effect on IL-12. Thus, the immune responses of HY8002 and HY7717 may be associated with PRRs such as other TLRs or NOD-like receptors (NLRs) [52]. TLR2 is a major receptor of both HY8002 and HY7717 and promotes immune activity in splenocytes. Weaning stress in piglets can suppress systemic immune responses, making piglets vulnerable to infectious diseases, including diarrhea. Jing Wang et al. reported that the supply of *Lactobacillus plantarum* improves intestinal health in weaned pigs by increasing the expression of host defense peptide (HDP) through TLR2 signaling [53]. Since HY7717 and HY8002 have the effect of improving systemic immunosuppression, they are expected to be effective in improving the immune load caused by weaning stress in piglets [54]. However, it may not be the sole receptor involved in this process. Therefore, further studies are needed on factors other than TLRs that may influence HY8002 and HY7717-mediated immune responses.

In this study, the combination of *Bifidobacterium animalis* ssp. *lactis* HY8002 and *Lactobacillus plantarum* HY7717 was more efficacious than either treatment alone at stimulating cytokine release in mouse primary splenocytes. HY8002 plus HY7717 effectively rehabilitated the splenic and hematological indices, NK cell activity, T and B cell proliferation, and immunoglobulin and cytokine production in a mouse CTX-induced immunosuppression model. The immunostimulatory effects of HY8002 and HY7717 were closely associated with TLR2. Hence, the combination of HY8002 and HY7717 effectively enhances immune function, suggesting the possibility of this combination as a probiotics for immune enhancement. Collectively, the combination of the two

probiotics would be considered a potential candidate to application of functional dairy foods.

REFERENCES

1. Crimeen-Irwin B, Scalzo K, Gloster S, Mottram PL, Plebanski M. Failure of immune homeostasis - the consequences of under and over reactivity. *Curr Drug Targets Immune Endocr Metabol Disord.* 2005;5:413-23. <https://doi.org/10.2174/156800805774912980>
2. Eghrari-Sabet JS, Hartley AH. Sweet's syndrome: an immunologically mediated skin disease? *Ann Allergy.* 1994;72:125-8.
3. Jung JY, Shin JS, Lee SG, Rhee YK, Cho CW, Hong HD, et al. *Lactobacillus sakei* K040706 evokes immunostimulatory effects on macrophages through TLR 2-mediated activation. *Int Immunopharmacol.* 2015;28:88-96. <https://doi.org/10.1016/j.intimp.2015.05.037>
4. Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, et al. Innate or adaptive immunity? The example of natural killer cells. *Science.* 2011;331:44-9. <https://doi.org/10.1126/science.1198687>
5. Arango Duque G, Descoteaux A. Macrophage cytokines: involvement in immunity and infectious diseases. *Front Immunol.* 2014;5:491. <https://doi.org/10.3389/fimmu.2014.00491>
6. Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: physiology, pathophysiology and pharmacology. *Pharmacol Rev.* 1991;43:109-42.
7. Ghosh S, May MJ, Kopp EB. NF- κ B and Rel proteins: evolutionarily conserved mediators of immune responses. *Annu Rev Immunol.* 1998;16:225-60. <https://doi.org/10.1146/annurev.immunol.16.1.225>
8. Seminario-Amez M, López-López J, Estrugo-Devesa A, Ayuso-Montero R, Jané -Salas E. Probiotics and oral health: a systematic review. *Med Oral Patol Oral Cir Bucal.* 2017;22:e282-8. <https://doi.org/10.4317/medoral.21494>
9. Singh K, Rao A. Probiotics: a potential immunomodulator in COVID-19 infection management. *Nutr Res.* 2021;87:1-12. <https://doi.org/10.1016/j.nutres.2020.12.014>
10. Popova M, Molimard P, Courau S, Crociani J, Dufour C, Le Vacon F, et al. Beneficial effects of probiotics in upper respiratory tract infections and their mechanical actions to antagonize pathogens. *J Appl Microbiol.* 2012;113:1305-18. <https://doi.org/10.1111/j.1365-2672.2012.05394.x>
11. Azad MAK, Sarker M, Wan D. Immunomodulatory effects of probiotics on cytokine profiles. *BioMed Res Int.* 2018;2018:8063647. <https://doi.org/10.1155/2018/8063647>
12. Nova E, Wörnberg J, Gómez-Martínez S, Díaz LE, Romeo J, Marcos A. Immunomodulatory effects of probiotics in different stages of life. *Br J Nutr.* 2007;98:S90-5. <https://doi.org/10.1017/S0007114507832983>
13. Neish AS. The gut microflora and intestinal epithelial cells: a continuing dialogue. *Microbes Infect.* 2002;4:309-17. [https://doi.org/10.1016/S1286-4579\(02\)01543-5](https://doi.org/10.1016/S1286-4579(02)01543-5)
14. Ren C, Cheng L, Sun Y, Zhang Q, de Haan BJ, Zhang H, et al. Lactic acid bacteria secrete toll like receptor 2 stimulating and macrophage immunomodulating bioactive factors. *J Funct Foods.* 2020;66:103783. <https://doi.org/10.1016/j.jff.2020.103783>
15. Lebeer S, Vanderleyden J, De Keersmaecker SCJ. Host interactions of probiotic bacterial surface molecules: comparison with commensals and pathogens. *Nat Rev Microbiol.* 2010;8:171-84. <https://doi.org/10.1038/nrmicro2297>
16. Ren C, Zhang Q, de Haan BJ, Zhang H, Faas MM, de Vos P. Identification of TLR2/TLR6 signalling lactic acid bacteria for supporting immune regulation. *Sci Rep.* 2016;6:34561. <https://doi.org/10.1038/srep34561>

17. Xiao J, Liang Z, Liu A, Chen D, Xiao Y, Liu J, et al. Immunosuppressive activity of polysaccharides from *Cordyceps gunnii* mycelia in mice in vivo/vitro. *J Food Agric Environ*. 2004;2:69-73.
18. Wang H, Wang M, Chen J, Tang Y, Dou J, Yu J, et al. A polysaccharide from *Strongylocentrotus nudus* eggs protects against myelosuppression and immunosuppression in cyclophosphamide-treated mice. *Int Immunopharmacol*. 2011;11:1946-53. <https://doi.org/10.1016/j.intimp.2011.06.006>
19. Al-Nasser IA. In vivo prevention of cyclophosphamide-induced Ca²⁺ dependent damage of rat heart and liver mitochondria by cyclosporin A. *Comp Biochem Physiol A Mol Integr Physiol*. 1998;121:209-14. [https://doi.org/10.1016/S1095-6433\(98\)10135-6](https://doi.org/10.1016/S1095-6433(98)10135-6)
20. Houssiau F. Thirty years of cyclophosphamide: assessing the evidence. *Lupus*. 2007;16:212-6. <https://doi.org/10.1177/0961203306075613>
21. Wohlgenuth S, Loh G, Blaut M. Recent developments and perspectives in the investigation of probiotic effects. *Int J Med Microbiol*. 2010;300:3-10. <https://doi.org/10.1016/j.ijmm.2009.08.003>
22. Kim JY, Bang SJ, Kim JY, Choi EJ, Heo K, Shim JJ, et al. The probiotic strain bifidobacterium animalis ssp. lactis HY8002 potentially improves the mucosal integrity of an altered intestinal microbial environment. *Front Microbiol*. 2022;13:817591. <https://doi.org/10.3389/fmicb.2022.817591>
23. Nam W, Kim H, Bae C, Kim J, Nam B, Lee Y, et al. Lactobacillus HY2782 and bifidobacterium HY8002 decrease airway hyperresponsiveness induced by chronic PM2.5 inhalation in mice. *J Med Food*. 2020;23:575-83. <https://doi.org/10.1089/jmf.2019.4604>
24. Jang SE, Joh EH, Lee HY, Ahn YT, Lee JH, Huh CS, et al. Lactobacillus plantarum HY7712 ameliorates cyclophosphamide-induced immunosuppression in mice. *J Microbiol Biotechnol*. 2013;23:414-21. <https://doi.org/10.4014/jmb.1210.10010>
25. Lee H, Ahn YT, Park SH, Park DY, Jin YW, Kim CS, et al. Lactobacillus plantarum HY7712 protects against the impairment of NK-cell activity caused by whole-body γ -irradiation in mice. *J Microbiol Biotechnol*. 2014;24:127-31. <https://doi.org/10.4014/jmb.1307.07001>
26. Meng Y, Li B, Jin D, Zhan M, Lu J, Huo G. Immunomodulatory activity of Lactobacillus plantarum KLDS1.0318 in cyclophosphamide-treated mice. *Food Nutr Res*. 2018;62. <https://doi.org/10.29219/fnr.v62.1296>
27. Shang J, Wan F, Zhao L, Meng X, Li B. Potential immunomodulatory activity of a selected strain Bifidobacterium bifidum H3-R2 as evidenced in vitro and in immunosuppressed mice. *Front Microbiol*. 2020;11:2089. <https://doi.org/10.3389/fmicb.2020.02089>
28. Claes IJ, Segers ME, Verhoeven TLA, Dusselier M, Sels BF, De Keersmaecker SCJ, et al. Lipoteichoic acid is an important microbe-associated molecular pattern of Lactobacillus rhamnosus GG. *Microb Cell Fact*. 2012;11:161. <https://doi.org/10.1186/1475-2859-11-161>
29. Sim I, Park KT, Kwon G, Koh JH, Lim YH. Probiotic potential of Enterococcus faecium isolated from chicken cecum with immunomodulating activity and promoting longevity in *Caenorhabditis elegans*. *J Microbiol Biotechnol*. 2018;28:883-92. <https://doi.org/10.4014/jmb.1802.02019>
30. Peng X, Zhang R, Duan G, Wang C, Sun N, Zhang L, et al. Production and delivery of Helicobacter pylori NapA in Lactococcus lactis and its protective efficacy and immune modulatory activity. *Sci Rep*. 2018;8:6435. <https://doi.org/10.1038/s41598-018-24879-x>
31. Jung IS, Jeon MG, Oh DS, Jung YJ, Kim HS, Bae D, et al. Micronized, heat-treated Lactobacillus plantarum LM1004 alleviates cyclophosphamide-induced immune suppression. *J Med Food*. 2019;22:896-906. <https://doi.org/10.1089/jmf.2018.4378>

32. Wells JM. Immunomodulatory mechanisms of lactobacilli. *Microb Cell Fact.* 2011;10:S17. <https://doi.org/10.1186/1475-2859-10-S1-S17>
33. Park IJ, Lee JH, Kye BH, Oh HK, Cho YB, Kim YT, et al. Effects of probiotics on the symptoms and surgical outcomes after anterior resection of colon cancer (POSTCARE): a randomized, double-blind, placebo-controlled trial. *J Clin Med.* 2020;9:2181. <https://doi.org/10.3390/jcm9072181>
34. Mo SJ, Nam B, Bae CH, Park SD, Shim JJ, Lee JL. Characterization of novel *Lactobacillus paracasei* HY7017 capable of improving physiological properties and immune enhancing effects using red ginseng extract. *Fermentation.* 2021;7:238. <https://doi.org/10.3390/fermentation7040238>
35. Whalley K. Brain–spleen link tunes immunity. *Nat Rev Immunol.* 2020;20:406-7. <https://doi.org/10.1038/s41577-020-0347-9>
36. Zhang JM, An J. Cytokines, inflammation, and pain. *Int Anesthesiol Clin.* 2007;45:27-37. <https://doi.org/10.1097/AIA.0b013e318034194e>
37. Trinchieri G. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. *Annu Rev Immunol.* 1995;13:251-76. <https://doi.org/10.1146/annurev.iy.13.040195.001343>
38. Chu WM. Tumor necrosis factor. *Cancer Lett.* 2013;328:222-5. <https://doi.org/10.1016/j.canlet.2012.10.014>
39. Mei Y, Chen H, Zhang J, Zhang X, Liang Y. Protective effect of chitooligosaccharides against cyclophosphamide-induced immunosuppression in mice. *Int J Biol Macromol.* 2013;62:330-5. <https://doi.org/10.1016/j.ijbiomac.2013.09.038>
40. Fu Y, Wang T, Xiu L, Shi X, Bian Z, Zhang Y, et al. Levamisole promotes murine bone marrow derived dendritic cell activation and drives Th1 immune response in vitro and in vivo. *Int Immunopharmacol.* 2016;31:57-65. <https://doi.org/10.1016/j.intimp.2015.12.015>
41. Yin J, Jin H, Yang F, Ding Z, Huang C, Zhu Q, et al. Synergistic effects of adjuvants interferon- γ and levamisole on DNA vaccination against infection with Newcastle disease virus. *Viral Immunol.* 2007;20:288-99. <https://doi.org/10.1089/vim.2006.0108>
42. Park HE, Lee WK. Immune enhancing effects of *Weissella cibaria* JW15 on BALB/c mice immunosuppressed by cyclophosphamide. *J Funct Foods.* 2018;49:518-25. <https://doi.org/10.1016/j.jff.2018.09.003>
43. Cheng VCC, Hung IFN, Wu AKL, Tang BSF, Chu CM, Yuen KY. Lymphocyte surge as a marker for immunorestitution disease due to *Pneumocystis jirovecii* pneumonia in HIV-negative immunosuppressed hosts. *Eur J Clin Microbiol Infect Dis.* 2004;23:512-4. <https://doi.org/10.1007/s10096-004-1140-6>
44. Karsten E, Herbert BR. The emerging role of red blood cells in cytokine signalling and modulating immune cells. *Blood Rev.* 2020;41:100644. <https://doi.org/10.1016/j.blre.2019.100644>
45. Minton K. Red blood cells join the ranks as immune sentinels. *Nat Rev Immunol.* 2021;21:760-1. <https://doi.org/10.1038/s41577-021-00648-2>
46. Abel AM, Yang C, Thakar MS, Malarkannan S. Natural killer cells: development, maturation, and clinical utilization. *Front Immunol.* 2018;9:1869. <https://doi.org/10.3389/fimmu.2018.01869>
47. Meng M, Wang H, Li Z, Guo M, Hou L. Protective effects of polysaccharides from *Cordyceps gunnii* mycelia against cyclophosphamide-induced immunosuppression to TLR4/TRAF6/NF- κ B signalling in BALB/c mice. *Food Funct.* 2019;10:3262-71. <https://doi.org/10.1039/C9FO00482C>

48. Oberg HH, Juricke M, Kabelitz D, Wesch D. Regulation of T cell activation by TLR ligands. *Eur J Cell Biol.* 2011;90:582-92. <https://doi.org/10.1016/j.ejcb.2010.11.012>
49. Hua Z, Hou B. TLR signaling in B-cell development and activation. *Cell Mol Immunol.* 2013;10:103-6. <https://doi.org/10.1038/cmi.2012.61>
50. Owens JA, Saeedi BJ, Naudin CR, Hunter-Chang S, Barbian ME, Eboka RU, et al. *Lactobacillus rhamnosus* GG orchestrates an antitumor immune response. *Cell Mol Gastroenterol Hepatol.* 2021;12:1311-27. <https://doi.org/10.1016/j.jcmgh.2021.06.001>
51. Castillo NA, Perdigón G, de Moreno de LeBlanc A. Oral administration of a probiotic *Lactobacillus* modulates cytokine production and TLR expression improving the immune response against *Salmonella enterica* serovar Typhimurium infection in mice. *BMC Microbiol.* 2011;11:177. <https://doi.org/10.1186/1471-2180-11-177>
52. Cortes-Perez NG, de Moreno de LeBlanc A, Gomez-Gutierrez JG, LeBlanc JG, Bermúdez-Humarán LG. Probiotics and trained immunity. *Biomolecules.* 2021;11:1402. <https://doi.org/10.3390/biom11101402>
53. Campbell JM, Crenshaw JD, Polo J. The biological stress of early weaned piglets. *J Anim Sci Biotechnol.* 2013;4:19. <https://doi.org/10.1186/2049-1891-4-19>
54. Wang J, Zhang W, Wang S, Liu H, Zhang D, Wang Y, et al. Swine-derived probiotic *Lactobacillus plantarum* modulates porcine intestinal endogenous host defense peptide synthesis through TLR2/MAPK/AP-1 signaling pathway. *Front Immunol.* 2019;10:2691. <https://doi.org/10.3389/fimmu.2019.02691>